SMSPHARMAPharmaceuticals
Sms Pharmaceuticals Ltd — Profit & Loss Statement
₹374.85
-5.18%
Sms Pharmaceuticals Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -0.01 Cr | -333.92 | — |
| Tax Rate For Calcs | 0.27 | 0.26 | 0.27 | 0.01 | — |
| Normalized EBITDA | 145.22 Cr | 121.08 Cr | 58.52 Cr | 118.81 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | -0.05 Cr | -37000.00 | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | -0.05 Cr | -37000.00 | — |
| Net Income From Continuing Operation Net Minority Interest | 69.14 Cr | 49.83 Cr | -7.06 Cr | 62.22 Cr | — |
| Reconciled Depreciation | 34.34 Cr | 31.52 Cr | 32.13 Cr | 32.15 Cr | — |
| Reconciled Cost Of Revenue | 523.41 Cr | 497.71 Cr | 390.61 Cr | 333.59 Cr | — |
| EBITDA | 145.22 Cr | 121.08 Cr | 58.47 Cr | 118.81 Cr | — |
| EBIT | 110.88 Cr | 89.56 Cr | 26.34 Cr | 86.66 Cr | — |
| Net Interest Income | -18.54 Cr | -23.46 Cr | -21.20 Cr | -18.60 Cr | — |
| Interest Expense | 18.54 Cr | 23.46 Cr | 20.99 Cr | 18.16 Cr | — |
| Normalized Income | 69.14 Cr | 49.83 Cr | -7.02 Cr | 62.22 Cr | — |
| Net Income From Continuing And Discontinued Operation | 69.14 Cr | 49.83 Cr | -7.06 Cr | 62.22 Cr | — |
| Total Expenses | 678.09 Cr | 624.16 Cr | 497.27 Cr | 432.55 Cr | — |
| Diluted Average Shares | 8.47 Cr | 8.46 Cr | 8.47 Cr | 8.47 Cr | — |
| Basic Average Shares | 8.47 Cr | 8.46 Cr | 8.47 Cr | 8.47 Cr | — |
| Diluted EPS | 8.16 | 5.89 | -0.83 | 7.35 | — |
| Basic EPS | 8.16 | 5.89 | -0.83 | 7.35 | — |
| Diluted NI Availto Com Stockholders | 69.14 Cr | 49.83 Cr | -7.06 Cr | 62.22 Cr | — |
| Net Income Common Stockholders | 69.14 Cr | 49.83 Cr | -7.06 Cr | 62.22 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 69.14 Cr | 49.83 Cr | -7.06 Cr | 62.22 Cr | — |
| Net Income Including Noncontrolling Interests | 69.14 Cr | 49.83 Cr | -7.06 Cr | 62.22 Cr | — |
| Net Income Continuous Operations | 69.14 Cr | 49.83 Cr | -7.06 Cr | 62.22 Cr | — |
| Tax Provision | 24.94 Cr | 16.91 Cr | 1.47 Cr | 0.62 Cr | — |
| Pretax Income | 92.34 Cr | 66.11 Cr | 5.35 Cr | 68.50 Cr | — |
| Other Non Operating Income Expenses | 6.22 Cr | 4.46 Cr | 0.22 Cr | 2.06 Cr | — |
| Special Income Charges | 0.00 | 0.00 | -0.05 Cr | -37000.00 | — |
| Net Non Operating Interest Income Expense | -18.54 Cr | -23.46 Cr | -21.20 Cr | -18.60 Cr | — |
| Interest Expense Non Operating | 18.54 Cr | 23.46 Cr | 20.99 Cr | 18.16 Cr | — |
| Operating Income | 104.65 Cr | 85.10 Cr | 22.48 Cr | 82.47 Cr | — |
| Operating Expense | 154.69 Cr | 126.45 Cr | 106.66 Cr | 98.96 Cr | — |
| Other Operating Expenses | 40.26 Cr | 30.79 Cr | 4.69 Cr | 4.55 Cr | — |
| Depreciation And Amortization In Income Statement | 34.34 Cr | 31.52 Cr | 32.13 Cr | 32.15 Cr | — |
| Depreciation Income Statement | 34.34 Cr | 31.52 Cr | 31.42 Cr | 31.44 Cr | — |
| Gross Profit | 259.34 Cr | 211.56 Cr | 129.14 Cr | 181.43 Cr | — |
| Cost Of Revenue | 523.41 Cr | 497.71 Cr | 390.61 Cr | 333.59 Cr | — |
| Total Revenue | 782.75 Cr | 709.26 Cr | 519.75 Cr | 515.02 Cr | — |
| Operating Revenue | 782.75 Cr | 709.26 Cr | 519.75 Cr | 515.02 Cr | — |
| Interest Income | — | 0.76 Cr | 0.77 Cr | 0.56 Cr | 0.31 Cr |
| Rent Expense Supplemental | — | 0.07 Cr | 0.08 Cr | 0.09 Cr | 0.10 Cr |
| Other Special Charges | — | -0.04 Cr | 0.05 Cr | 37000.00 | 80000.00 |
| Total Other Finance Cost | — | 0.98 Cr | 0.98 Cr | 1.01 Cr | 0.94 Cr |
| Interest Income Non Operating | — | 0.76 Cr | 0.77 Cr | 0.56 Cr | 0.31 Cr |
| Amortization | — | 0.91 Cr | 0.71 Cr | 0.71 Cr | 0.43 Cr |
| Research And Development | — | 11.11 Cr | 8.92 Cr | — | — |
| Selling General And Administration | — | 14.21 Cr | 9.32 Cr | 8.37 Cr | 9.20 Cr |
| Selling And Marketing Expense | — | 4.73 Cr | 3.82 Cr | 3.42 Cr | 5.09 Cr |
| General And Administrative Expense | — | 9.47 Cr | 5.50 Cr | 4.95 Cr | 4.11 Cr |
| Rent And Landing Fees | — | 0.07 Cr | 0.08 Cr | 0.09 Cr | 0.10 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Sms Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.